NASDAQ:ZFGNZafgen Stock Price, Forecast & News

$12.30

+0.42 (+3.54 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$10.00

Now: $12.30▼

$12.51

50-Day Range

$0.76

MA: $0.86▼

$1.16

52-Week Range

$0.62

Now: $12.30▼

$2.76

Volume61,252 shs

Average Volume990,712 shs

Market Capitalization$460.88 million

P/E RatioN/A

Dividend YieldN/A

Beta0.27

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Beat the Market (BTM) Rank^™

1.0 Analyst's Opinion

Consensus Rating
Zafgen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $0.78, Zafgen has a potential downside of 93.7% from its current price of $12.30.
Amount of Analyst Coverage
Zafgen has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Zafgen has received 345 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zafgen has received 316 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zafgen has received 52.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote “Outperform” if you believe ZFGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zafgen does not currently pay a dividend.
Dividend Growth
Zafgen does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zafgen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 14.20% of the stock of Zafgen is held by insiders.
Percentage Held by Institutions
70.43% of the stock of Zafgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Zafgen is -12.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zafgen is -12.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zafgen has a P/B Ratio of 9.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.92 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZFGN

Previous Symbol

CUSIPN/A

CIK1374690

Webwww.zafgen.com

Phone617-622-4003

Debt

Debt-to-Equity Ratio0.26

Current Ratio6.56

Quick Ratio6.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.35 per share

Price / Book9.11

Profitability

EPS (Most Recent Fiscal Year)($1.07)

Net Income$-45,410,000.00

Net MarginsN/A

Return on Equity-51.34%

Return on Assets-34.55%

Miscellaneous

Employees38

Outstanding Shares37,470,000

Market Cap$460.88 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

How has Zafgen's stock been impacted by COVID-19 (Coronavirus)?

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 1,346.9% and is now trading at $12.30. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zafgen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen.

When is Zafgen's next earnings date?

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zafgen.

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. View Zafgen's earnings history.

What price target have analysts set for ZFGN?

3 brokerages have issued 12-month price objectives for Zafgen's stock. Their forecasts range from $0.78 to $0.78. On average, they anticipate Zafgen's stock price to reach $0.78 in the next year. This suggests that the stock has a possible downside of 93.7%. View analysts' price targets for Zafgen.

Has Zafgen been receiving favorable news coverage?

News coverage about ZFGN stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zafgen earned a news impact score of -4.6 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near term. View the latest news aboutZafgen.

Are investors shorting Zafgen?

Zafgen saw a drop in short interest in May. As of May 15th, there was short interest totaling 523,100 shares, a drop of 9.4% from the April 30th total of 577,100 shares. Based on an average trading volume of 182,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 1.8% of the company's shares are short sold. View Zafgen's Current Options Chain.

Who are some of Zafgen's key competitors?

Some companies that are related to Zafgen include Rockwell Medical (RMTI), Aldeyra Therapeutics (ALDX), BIOFRONTERA AG/ADR (BFRA), Sierra Oncology (SRRA), Minerva Neurosciences (NERV), Conatus Pharmaceuticals (CNAT), Evelo Biosciences (EVLO), Trevena (TRVN), Harrow Health (HROW), Theratechnologies (THTX), Zynerba Pharmaceuticals (ZYNE), AVEO Pharmaceuticals (AVEO), Endonovo Therapeutics (ENDV), SUMMIT THERAPEU/S (SMMT) and Savara (SVRA). View all competitors.

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), SCYNEXIS (SCYX), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Esperion Therapeutics (ESPR) and Gilead Sciences (GILD).

Who are Zafgen's key executives?

Zafgen's management team includes the following people:

Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Who are Zafgen's major shareholders?

Zafgen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (8.44%), Soleus Capital Management L.P. (3.60%), Orbimed Advisors LLC (2.95%), Russell Investments Group Ltd. (0.70%), Two Sigma Investments LP (0.60%) and Two Sigma Advisers LP (0.57%). View institutional ownership trends for Zafgen.

Which major investors are selling Zafgen stock?

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Russell Investments Group Ltd., Hikari Power Ltd, and Two Sigma Advisers LP. View insider buying and selling activity for Zafgen.

Which major investors are buying Zafgen stock?

ZFGN stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Soleus Capital Management L.P., and Orbimed Advisors LLC. View insider buying and selling activity for Zafgen.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $12.30.

How big of a company is Zafgen?

Zafgen has a market capitalization of $460.88 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

What is Zafgen's official website?

The official website for Zafgen is www.zafgen.com.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff